NAS10027,087+1.72%S&P7,401+0.65%GOLD$4,073−1.00%BTC$75,828−0.15%VIX24.55−12.88%latest tape · as of 20:03 UTC
The Screen · Healthcare · Health Information Services
CTEVClaritev Corp
CTEV · the NYSE · USD · Market cap $518M · 3,000 employees
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States.
FAIL · Does not pass the screen
20.22 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price20.22 USD at the 5 Nov 2026 close
Fair valueUnder review: our model's value is 2.02x the price, above our 2.00x limit.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.23, read 2026-11-04
Ethical does not pass the values gate
Price20.22 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-05Read Markdown21.67-6.7% to today ✓Accumulation gives way to Markdown after an 8% slide in 7 days
2026-10-29Read Accumulation23.50-14.0% to today Markdown gives way to Accumulation after a 26% slide in 4 weeks
2026-10-02Read Markdown31.62-36.1% to today ✓Markup gives way to Markdown with volume flow in agreement
2026-07-02Read Markup30.89-34.5% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Claritev Corp holds its Markdown at $20.22. The statistical read favours the sellers, held for 38 days.
As held on the ledger · 2026-11-05
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 38 days
Price at the screen
$20.22
Valuation
N/A trailing · 4.62 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.70
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
94.43%
Below 33%
Interest-bearing debt is 94.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
2.95%
Below 49%
Money owed to the company is 3.0% of assets, under the 49% limit.
Pass
Revenue purity
0.16%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Claritev's business is in a permissible area, but its interest-bearing debt is about 94% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CTEV's ethical verdict changes
Today CTEV does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.02x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CTEV trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-06Markdown$20.22-6.7%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Markdown · changed$21.67+3.2%Entry 13
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Accumulation$21.00-12.5%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 12.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$24.00+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$24.00+2.1%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37. Insiders have been net sellers over the past quarter.
2026-10-22Markdown$23.86-3.2%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37. Insiders have been net sellers over the past quarter.
2026-10-15Markdown$24.66-22.0%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 22.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37.
2026-10-02Markdown · changed$31.62+4.0%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37.
2026-08-26Markup$30.39+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $37.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.